Mariano Provencio-Pulla

31PUBLICATIONS
272CO-AUTHORS
Predictive and prognostic markersSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|May 21, 2026
Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer.

|Apr 15, 2026
Mediastinal staging and restaging techniques in locally advanced non-small cell lung cancer in the era of neoadjuvant and perioperative chemoimmunotherapy-a narrative review.

María Izquierdo-Chamarro, Aylen Vanessa Ospina-Serrano, Mariano Provencio-Pulla

|Mar 10, 2026
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Belén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre

|Feb 17, 2026
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Ben Tran, Mark Voskoboynik, Sang-We Kim

|Jan 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.

Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal

|Jan 08, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.

Mariano Provencio, Mark M Awad, Jonathan D Spicer

Pageof 6

Frequent Collaborators

9 joint publications

Alberto Cruz-Bermúdez

8 joint publications

Ernest Nadal

8 joint publications

Virginia Calvo

8 joint publications

Javier De Castro Carpeño